
News|Articles|July 7, 2026
Q2 2026 Recap: Dermatology News & Updates
Author(s)Tim Smith
Fact checked by: Ryan Livingston
This review highlights the most notable dermatology news stories covered by HCPLive during the second quarter of 2026.
Advertisement
Advertisement
During the second quarter of 2026, a series of notable events took place in the field of dermatology, including the release of emerging clinical data, new regulatory advancements, and the general evolution of treatment paradigms, reshaping the management of inflammatory skin diseases. Stories regarding new
Related to this article

Experts outline when to stop cycling topical steroids in chronic hand eczema and where topical delgocitinib now fits.

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.

A post hoc, unmatched comparison presented at ACAAI 2026 found similar 14-day improvements in urticaria activity with omalizumab vs remibrutinib.

Oral icotrokinra beat placebo and was noninferior to ustekinumab in moderate to severe plaque psoriasis in the phase 3 ICONIC-ASCEND trial.

Leigh Ann Pansch, MSN, FNP-BC, DCNP, discusses year-round photoprotection, missed skin cancer detection, and overlooked patients for Healthy Skin Month.

Post hoc analyses at ACAAI 2026 show 41.7% of patients-maintained CSU control and quality of life 16 weeks after stopping omalizumab.
Advertisement
Advertisement

